These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34517473)

  • 1. An efficient and flexible multiplicity adjustment for chi-square endpoints.
    Wagler A; McCann M
    Math Biosci Eng; 2021 Jun; 18(5):4971-4986. PubMed ID: 34517473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of multiplicity adjustment strategies for correlated binary endpoints.
    Leon AC; Heo M
    J Biopharm Stat; 2005; 15(5):839-55. PubMed ID: 16080237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The issue of multiplicity in noninferiority studies.
    Ke C; Ding B; Jiang Q; Snapinn SM
    Clin Trials; 2012 Dec; 9(6):730-5. PubMed ID: 22879575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical power of multiplicity adjustment strategies for correlated binary endpoints.
    Leon AC; Heo M; Teres JJ; Morikawa T
    Stat Med; 2007 Apr; 26(8):1712-23. PubMed ID: 17252534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.
    Quan H; Luo X; Capizzi T
    Stat Med; 2005 Jul; 24(14):2151-70. PubMed ID: 15909290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical planning to address strongly correlated endpoints for inferential subgroups: An innovative approach for an illustrative clinical trial with complex multiplicity issues.
    Sun H; Binkowitz B; Koch GG
    J Biopharm Stat; 2017; 27(3):399-415. PubMed ID: 28267412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size determination with familywise control of both type I and type II errors in clinical trials.
    Wang B; Ting N
    J Biopharm Stat; 2016; 26(5):951-65. PubMed ID: 26881972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weighted analysis of composite endpoints with simultaneous inference for flexible weight constraints.
    Duc AN; Wolbers M
    Stat Med; 2017 Feb; 36(3):442-454. PubMed ID: 27782312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Part 1. Statistical Learning Methods for the Effects of Multiple Air Pollution Constituents.
    Coull BA; Bobb JF; Wellenius GA; Kioumourtzoglou MA; Mittleman MA; Koutrakis P; Godleski JJ
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):5-50. PubMed ID: 26333238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighted false discovery rate controlling procedures for clinical trials.
    Benjamini Y; Cohen R
    Biostatistics; 2017 Jan; 18(1):91-104. PubMed ID: 27445132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bonferroni-based correction factor for multiple, correlated endpoints.
    Shi Q; Pavey ES; Carter RE
    Pharm Stat; 2012; 11(4):300-9. PubMed ID: 22588983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing multiple endpoints in a confirmatory randomized clinical trial-an approach that addresses stratification, missing values, baseline imbalance and multiplicity for strictly ordinal outcomes.
    Sun H; Kawaguchi A; Koch G
    Pharm Stat; 2017 Mar; 16(2):157-166. PubMed ID: 28074600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A graphical weighted power improving multiplicity correction approach for SNP selections.
    Saunders G; Fu G; Stevens JR
    Curr Genomics; 2014 Oct; 15(5):380-9. PubMed ID: 25435800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fallback procedure for evaluating a single family of hypotheses.
    Wiens BL; Dmitrienko A
    J Biopharm Stat; 2005; 15(6):929-42. PubMed ID: 16279352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified truncated Hochberg procedure for multiple endpoints: An application in a confirmatory trial for pediatric functional constipation.
    Chen J; Thakur M; Zeng H; Gabriel A
    Contemp Clin Trials; 2023 Jun; 129():107185. PubMed ID: 37059263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing power while controlling family-wise error: an illustration of the issues using electrocortical studies.
    Yoder PJ; Blackford JU; Waller NG; Kim G
    J Clin Exp Neuropsychol; 2004 May; 26(3):320-31. PubMed ID: 15512923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An introduction to multiplicity issues in clinical trials: the what, why, when and how.
    Li G; Taljaard M; Van den Heuvel ER; Levine MA; Cook DJ; Wells GA; Devereaux PJ; Thabane L
    Int J Epidemiol; 2017 Apr; 46(2):746-755. PubMed ID: 28025257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling the family-wise error rate in multi-arm, multi-stage trials.
    Crouch LA; Dodd LE; Proschan MA
    Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating the sample correlation into the testing of two endpoints in clinical trials.
    Sarkar S; Rom D; McTague J
    J Biopharm Stat; 2021 Jul; 31(4):391-402. PubMed ID: 33909544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weighted multiple testing correction for correlated tests.
    Xie C
    Stat Med; 2012 Feb; 31(4):341-52. PubMed ID: 22114000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.